The concept of tumour markers has widened over the years and the term itself is much more recent than the basic idea. In the early 1930s Zondek clearly thought of detecting human chorionic gonatrophin (hCG) in body fluids to diagnose trophoblastic tumours of gestational and germ cell origin. Monitoring the course of these tumours with semiquantitative assays was described in the 1940s (Zondek, 1942; Hamburger, 1958; Hinglais & Hinglais, 1949) . Now the term has come to be applied to any means, usually of a chemical nature, which helps to discriminate between one type of tumour and other normal or disease states in a clinically useful way. In trying to present an overview of this now very large field I shall confine myself to the major substances on the scene, to solid tumours and largely to our studies at Charing Cross over the past 25 years. Much of the work to which I shall refer has been that of many colleagues, medical and scientific, past and present. Tumour markers, insofar as they exist, have potentially large applications as screening tests for cancer, as tests for cancer in the symptomatic patient, as a means of monitoring the course of disease and of detecting relapse at an early stage, in targeting isotopes to localise tumours and possibly in directing therapeutic agents.
It seems unlikely that a single marker will be ideal for all these applications even with respect to a single type of cancer; indeed the requirements for different purposes may be mutually exclusive.
Markers exist which can demonstrate all these different roles but unfortunately they have been identified so far, in clinically useful forms, for only a modest proportion of tumours.
Cancer tests
Rather little has been said about cancer Makari, 1955; Tee & Munson, 1977 Lewis Test Lewis et al., 1966 T Globulin Tal & Halperin, 1970 Herberman, 1977 (Field & Caspary, 1970) and the Structuredness of Cytoplasmic Matrix or SCM Test (Cercek & Cercek, 1977) . Both of these tests were based on sensitisation of the cancer patients' lymphocytes to myelin basic protein or a closely related substance and their proponents cooperated with others who later became involved in further evaluation. The first impressive claims, which in the case of the SCM tests, were for better than 99.5% correct results, were followed by confirmatory reports (Pritchard et al., 1972 (Pritchard et al., , 1978 . Nevertheless, their evaluation took several years to achieve and the cost probably ran into several millions of pounds before it became clear that they were unlikely to be clinically useful (Bagshawe et al., 1977; Mitchell et al., 1980; Balding et al., 1980 It is I think not inconceivable that there could result a significant shift in the use of medical resources from the management of the sick to the investigation of the healthy.
Even so, the temptation to pharmaceutical houses to launch into this field is almost overwhelming. There is therefore a responsibility on those involved in evaluating such tests to be particularly cautious in their enthusiasm. Many evaluations end with some blandishment such as "this should prove a useful test" simply because a significant difference has been demonstrated between a group of cancer patients, often with advanced disease, and a group of controls. The controls may be normal healthy people and rarely are they composed of those patients with obscure non-malignant diseases that do present difficult diagnostic problems. A statistically significant difference existing between cancer and non-cancer groups is of limited value when translated to the individual patients (Gray et al., 1982; Pentycross 1982) . How does it help the doctor confronted by the patient with an unexplained symptom, such as anorexia? "You have a positive cancer test, but don't worry there's a one in ten chance it's wrong"?
It would be reckless to try to set a level of accuracy at which a cancer test would become an acceptable asset. The more reliable the test the less frequent the problem of the false positive but the corollary of this would be the greater necessity to investigate every positive. No doubt there could be a point where benefits would exceed the penalties and it can only be hoped that reagent control agencies as well as pharmaceutical companies will continue to exercise great caution.
It is worth considering that these problems might be peculiar to the "all or none" concept of a single general cancer test. It is possible that if the same quality of information were to be ascertained from a series of independent tests requiring evaluation by some form of multivariate analysis then it might be less emotive. The elements of clinical judgement and uncertainty and the probabilities of different methods of data analysis might ease the situation. It is just possible that there would be more latitude in making the decision whether to perform the tests and the action that would need to be taken in the event of a high probability result being obtained.
Markers for particular types of cancer I have argued that a general test for cancer would need to have a very high degree of specificity but when we turn to tests for individual tumours we can turn that argument on its head. If we waited for absolute specificity there would be no tests at all. Yet there are some clinical situations where the use of a marker associated with particular tumours can be decisive even in primary diagnosis. "Acute orchitis" with a positive test for hCG or AFP is not "acute orchitis", but we still see young men die because their doctor didn't ask for a simple test. And a positive pregnancy test persisting for 6 months in a young woman with a flat abdomen indicates something more sinister than a pregnancy. Claims have been made for highly specific tumour markers but none so far have withstood close scrutiny and a tumour specific marker may well be defined as one that hasn't been properly investigated. Present serum markers may also be used in the primary diagnosis situation to distinguish between say a seminoma and an embryonal carcinoma of the testis or to distinguish a medullary carcinoma of the thyroid before surgery. Here we are not confronted by the emotive content of the general "cancer test" and the challenge is to exploit whatever information is available.
Human chorionic gonadotrophin was perhaps the first tumour marker to have been identified, also it arguably remains the most specific. Yet it is of course far from specific in the sense that it is also a marker for pregnancy and for a range of tumours that produce it as an ectopic product.
As a serological marker for trophoblastic activity hCG has formed the basis of the only practical biochemical screening programme yet established. Thus, in the UK patients with pregnancies resulting in hydatidiform mole are screened on the basis of their hCG values in serum or urine and those 10% or so who require treatment by various criteria can be clearly identified. This is the ideal situation for screening; a well defined population of young adults at high risk, for a limited period, to a potentially fatal tumour, which if identified at an early stage can almost always be eradicated and in most cases without significant toxicity or impairment of fertility .
It is difficult at present to identify any other possible primary tumour screening operations based on serological markers. Alphafetoprotein (aFP) was looked at as a means of detecting early hepatomas in a high risk population but found wanting with the methods then available (Purves, 1973) and a similar result has been reported recently (Watanabe & Nagashina, 1981) . Although it seems likely that we will have to await new markers before further biochemical screening can be undertaken for cancer there is the potential use of viral screens to identify high risk populations for hepatocellular and nasopharyngeal carcinomas and the use of occult blood tests to detect colorectal cancer.
Prognosis
The concentration of a secreted tumour product in serum should ideally reflect the total body burden of viable tumour. For some markers at any rate this appears to be true and for hCG this has been amply confirmed in the clinical context (Bagshawe, 1969) as well as in the nude mouse xenografted with choriocarcinoma (Searle et al., 1981) . Production of hCG in vitro and by small residual tumour masses in vivo has been studied and has provided a crude approximation which allows us to relate hCG values to the body burden of viable cells (Bagshawe, 1973) . On the other hand the correlation between serum concentration and tumour bulk is much less well defined for CEA both in the human subject and in the nude mouse xenografted with CEA producing human colonic cancer (Lewis & Keep, 1981) .
It is widely accepted that, other things being equal, the greater the total body burden of tumour the worse the prognosis and this was illustrated in a review of some 317 patients with trophoblastic tumours treated between 1957 and 1973 (Bagshawe, 1976 (Hertz et al., 1958; Bagshawe & Brooks 1959) .
Similarly for the germ cell tumours hCG and aFP provide a guide that is sensitive but has still to be assessed in the context of radiological evidence. For hepatoma we have of course a good marker in aFP but this tumour illustrates the point that a marker only shows its real value when there is effective treatment.
It would serve no useful purpose here to review superficially the other markers in current clinical use. Appreciation of their limitations is important but should not obscure recognition of the situations where they can be useful. New markers are commonly proposed and the promise of the monoclonal antibody revolution has still to be felt in the solid tumour clinic. The possibility that epitopes defined by monoclonal antibodies may occur on more than one protein is an additional twist on the road to specificity.
More specific markers may be found, and the search for them must be continued but the challenge is to learn to exploit the limited specificities we already have and can expect to have more of in the future. Immunocytochemistry mainly with enzymatic methods has become established, even if somewhat patchily, as an aid to histopathology. Whilst pathologists find it valuable its universal acceptance is likely to be dependent on better markers becoming available for the solid tumours. It is notable that whereas serum CEA is elevated in only about 50% of patients with colorectal cancer, it has been demonstrable by immunocytochemistry in tumour tissue in virtually all cases studied including a series of 50 cases at Charing Cross. It is perhaps the regular demonstration of such markers in human cancer that has triggered interest in the field of targeting.
Radioimmunolocalisation
Since the studies of Pressman & Korngold (1953) , Quinones et al. (1971) and Primus et al. (1973) showing the localisation of radiolabelled antibodies in experimental tumours the feasibility of radioimmunolocalisation (RIL) in man has been amply demonstrated (Goldenberg et al., 1978; Dykes et al., 1980; Mach et al., 1980; Searle et al., 1980; Farrands et al., 1982) . In our experience of almost 200 such scans at Charing Cross using mainly hCG or CEA as the target antigens, it can be said that there have been some instances where the technique has provided clinically useful information, leading in some cases to successful tumour resections, where other methods of tumour localisation including computerised tomography and ultrasound had failed or had been equivocal (Begent et al., 1982) .
Obviously the ultimate question is how RIL competes with and complements the other methods of tumour localisation. All imaging methods are in an evolutionary stage. In addition to radionuclide scanning and ECAT scanners we see sontinued developments in CT scanning and ultrasound, and the emergence of nuclear magnetic resonance (NMR) (Smith, 1981) and positron emission tomography (PET) (Hoffman et al., 1976) . It is clearly going to take many years for each of these highly complex developments to reach the peak of efficiency. The problem of evaluationg them individually and of determining the most effective and economic way to deploy these powerful tools in relation to each other is daunting. The antigenic targets studied by RIL to date have mainly been the secreted antigens hCG, aFP and CEA but there are interesting studies also with melanoma antigens (Larson et al., 1983) , and other antigenic targets (Epenetos et al., 1982; Farrands et al., 1982) . The ability to achieve tumour localisation in the presence of high concentrations of antigen in serum and other body fluids is interesting but we do not yet know whether it is better to have antibodies of high avidity or whether a particular immunoglobulin class is superior for this purpose, or whether antibody fragments are advantageous compared with intact immunoglobulin. Although there would seem to be no intrinsic advantage in monoclonal rather than polyclonal antibodies for RIL, monoclonals have some obvious practical advantages in helping to resolve some of these questions. Moreover, if multiple antigens make better targets than single antigens then monoclonals offer us the unequivocal advantages of controlled and reproducible reagents.
We do not yet know whether it is better to have as the target a secreted antigen or one bound to the cell membrane. It is often assumed that the latter would be better but few non-secreted markers of comparable specificity have been adequately studied. Clearly the central problem with RIL is to achieve the maximum contrast between tumour and background. Antigenic expression and secretion may be open to modification (Biquard & Aupoix, 1978; Browne & Bagshawe, 1982) . The "subtraction" technique (Goldenberg et al., 1978) which first made RIL possible has the serious disadvantage that it is somewhat arbitrary. It may be that certain classes of antibody localise in tumours and yet clear quickly from body fluids. Alternatively, the removal of circulating antibody may be accelerated by other means. This has been shown both in animals and in man by giving a second antibody directed at the first, radiolabelled antibody. We have found that by encapsulating the second antibody in liposomes the concentration of first antibody in serum is rapidly reduced through uptake in the reticuloendothelial system without a comparable reduction in the tumour concentration. Some other potential hazards of immune complex formation may also be minimised by this technique (Begent et al., 1982) .
The fact that antibodies can be shown to localise in tumours both by immunocytochemistry and by RIL has been a spur to therapeutic studies. Ironically, if antibody targeting in the therapeutic context were to succeed it would of course provide the lowest cost solution to the imaging problem by largely extinguishing the need for tumour localisation.
Drug/Antibody targeting The complement dependent cytotoxic action of antibodies has long been known but has proved inconsistent in many attempted studies. Recently there has been interest in the possibility that one class of IgG (Herlyn et al., 1980; Sears et al., 1982) or the use of univalent antibody (Glennie & Stevenson, 1982) may be cytotoxic. Nevertheless most interest at present focuses on drug/antibody combinations. The antibody targeted approach results from our failure so far to develop cell inhibiting agents of sufficient selectivity so the principle here is to produce a favourable differential distribution of non-selective agents.
A substantial literature has built up in the past two decades around the possibility of developing anti cancer agents with improved therapeutic/toxicity ratios by combining a drug or isotope with an antibody directed at a tumour antigen. The idea, of course, goes back to Ehrlich. It will not be possible to review this field in depth here but since our studies in tumour markers have from their beginning been broadly directed towards this possibility I propose to comment on the present scheme. Any idea that one has simply to couple a cytotoxic drug to an antitumour antibody to achieve a highly selective antitumour agent is dispelled by the number of papers reporting such approaches at the experimental level and the paucity of published clinical results (Ghose et al., 1982; Dullens et al., 1979; Rowland et al., 1975) . The fact that only a fraction of 1% of administered antibody has been retained in tumours (Mach, 1980) emphasises just one of the difficulties. In RIL the gamma camera and computer enhance the distinction between tumour and background but in drug targeting there is the additional problem of absolute concentrations and the time for which they are maintained both in tumour target and in susceptible normal tissues.
One assumption that has been widely made in these studies is that antibody or antibody/conjugate directed at a tumour-associated antigen finds its way to the cell membrane and becomes membrane bound. In reality it seems more analogous to a leaking sieve than a magic bullet. Thus, the drugs selected have been such as to require penetration into the cytoplasm of the target cells and the popularity of the ribosome-inactivating proteins such as the A chain of diphtheria toxin and ricin illustrate this. It is of course one thing to demonstrate binding to a cell surface in vitro, or to ascitic tumour cells by i.p. injection, and another to demonstrate that an intravenously-delivered antibody conjugate reaches the cell membranes of a high proportion of cells in a solid tumour in effective concentration. An order of magnitude difference between in vitro and in vivo concentrations has been found in one study (Larson et al., 1983) . It might be expected that the ability of an antibody to reach the cell surface depends on whether the antigen is secreted or freely shed. Autoradiographic studies in our laboratory with anti-CEA in mice xenografted with human colonic tumours have shown that the highest concentration of antibody is in the extracellular fluid space and in extracellular debris (Lewis et al., 1982) . At the same time this study does, however, suggest that a small amount of antibody is internalised by tumour cells and the effect is specific in that more anti-CEA than non-specific antibody localises in the cytoplasm of CEA-producing cells.
It can be argued that the concentration of antibody in the extra-cellular fluid space is a good reason for not using a secreted antigen as the target. The problem is that, so far, there is a shortage of membrane-bound antigens which have been characterised sufficiently to show they have sufficient specificity for clinical purposes. Autoradiographic studies of an antibody directed at a supposedly membrane bound antigen appear to show a similar distribution to that of anti-CEA (Epenetos et al., 1982) so that even where immunocytochemical and other studies suggest that an antigen is membrane bound in vivo, autoradiography is needed to confirm this. Of the monoclonal antibodies we have tested so far only one has shown marked affinity for binding to tumour cell membranes.
For drugs which must penetrate the cell membrane to exert their effect an antibody which binds to the cell surface in vivo is a first requirement. The in vivo distribution of antibodies to tumour-associated antigens requires detailed study before they can be properly used in the clinical situation with cytotoxins. Almost 20 years after the discovery of CEA its distribution in normal and malignant tissues is still being defined. The process will need speeding up. Clearly, finding an antigen in a normal tissue may or may not be a limitation and depends in part on whether that tissue is vital to life. But the specificity or lack of specificity of tumour-associated antigens remains, I suggest, one of the main obstacles to progress.
Even with a tumour-associated membrane bound antigen of adequate specificity there are likely to remain other problems. Do all the stem cells express the antigen or is it only expressed by cells which have differentiated? HCG for instance is only produced by syncytiotrophoblast and not by the stem cell cytotrophoblast. Heterogeneity of antigen expression could be a serious limitation. Again, there is the question whether in the presence of antibody will the antigen patch, or cap, or modulate?
The possibility of improving the overall specificity of the delivery system and of increasing antibody concentration by using antibodies directed at more than one antigen is already under investigation. It is analogous to the use of combination chemotherapy with a dispersal of toxic effects on normal tissues but a summation of them on the target. Also, there is the possibility of producing hybrid antibodies with specificities for more than one antigen (Nisonoff & Rivers, 1961) and hybrid antibodies in which one Fab fragment binds to the target and the other binds to the drug (Raso, 1982 distance of some microns from the cell surface the "warhead" needs to be capable of either being selectively released within the tumour or of being able to exert its effect at "long" range.
Long range effects may be achieved by radiation sources. Alpha emitters such as 211Astatine have the attraction of requiring only a very small number of hits on the cell (Bloomer et al., 1981) but it may prove difficult to handle the 99.9% of isotope which doesn't get into the tumour. Studies with "3'I-anti CEA in patients with advanced cancer have been described (Ettinger et al., 1982) and our calculations of radiation delivery to tumours are in broad agreement with this report. Small tumours may prove better targets than large tumours. Better isotopes may be available and ways of improving tumour to non-tumour discrimination and of protecting normal tissue are open to development.
Another possibility in which we have been interested is that of using metabolite-depleting enzymes. In conjunction with Dr R. Sherwood of the Centre of Applied Microbiology and Research at Porton Down we have been investigating the use of a folate-splitting carboxypeptidase coupled to antibodies directed at secreted antigens. An effect on the in vitro growth of a choriocarcinoma cell line has been demonstrated with carboxypeptidase. Antibodies to hCG have been coupled with carboxypeptidase whilst preserving the specific characteristics of both molecules (Searle, unpublished) . One problem is to maintain an effective concentration of the enzyme in the tumour extra cellular fluid for a long enough period and it seems likely that carboxypeptidase may achieve its best results in conjunction with conventional cytotoxic therapy aimed at blocking other metabolic pathways. There are, of course, other targetable enzymes to investigate.
One of the attractions of work in the tumour marker field at present is the large number of directions in which it might develop. In all directions the obstacles are formidable and the study of markers for the solid tumours has presented many pitfalls and disappointments in the last 25 years. Yet it has continued to grow and the possibility that it may have an impact on therapy gives the whole field new impetus. The success of any application of tumour markers ultimately depends on the degree of discrimination that markers provide and it is important that the search for such markers should continue however monotonous the study and however frequent the disappointment. 
